Parallax Volatility Advisers
BBIO icon

Parallax Volatility Advisers’s BridgeBio Pharma BBIO Stock Holding History

Parallax Volatility Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,538
Closed -$424K – 1473
2025
Q4 		$424K Buy
5,538
+963
+21% +$63.2K ﹤0.01% 1255
2025
Q3 		$238K Sell
4,575
-551
-11% -$26.9K ﹤0.01% 1351
2025
Q2 		$221K Buy
+5,126
New +$186K ﹤0.01% 1312
2025
Q1 		– Sell
-15,629
Closed -$527K – 1582
2024
Q4 		$429K Buy
+15,629
New +$404K ﹤0.01% 1535
2023
Q3 		– Sell
-365
Closed -$10.4K – 2286
2023
Q2 		$6.28K Sell
365
-75
-17% -$1.13K ﹤0.01% 2212
2023
Q1 		$7.29K Buy
+440
New +$5.13K ﹤0.01% 2437
2021
Q4 		– Sell
-27,671
Closed -$1.3M – 3002
2021
Q3 		$1.3M Sell
27,671
-59,134
-68% -$3.17M ﹤0.01% 1859
2021
Q2 		$5.29M Buy
86,805
+1,982
+2% +$113K ﹤0.01% 1192
2021
Q1 		$5.22M Buy
+84,823
New +$5.55M ﹤0.01% 1260

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallax Volatility Advisers's BBIO Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 5,538 shares — an estimated $424K sold.

Parallax Volatility Advisers first reported a position in BBIO in Q1 2021 and held it in 9 quarters. The position peaked at $5.29M in Q2 2021. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Parallax Volatility Advisers reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,538 BridgeBio Pharma shares in Q1 2026, an estimated $424K.
  • Parallax Volatility Advisers first reported a position in BridgeBio Pharma in Q1 2021 and held it in 9 quarters.
  • Parallax Volatility Advisers's BridgeBio Pharma position peaked at $5.29M in Q2 2021.
  • 460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.